Loading...
Loading...
Mylan Inc.
MYL today
announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has
launched Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35
mg, are the generic version of Janssen Pharmaceuticals, Inc.'s Micronor®
Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of
pregnancy. Mylan's partner, Famy Care Ltd., received final approval from the
U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug
Application (ANDA) for this product.
Norethindrone Tablets USP, 0.35 mg, had U.S. sales of approximately $57.2
million for the 12 months ending March 31, 2013, according to IMS Health.
Currently, Mylan has 176 ANDAs pending FDA approval representing $83 billion
in annual sales, according to IMS Health. Thirty-four of these pending ANDAs
are potential first-to-file opportunities, representing $22.5 billion in
annual brand sales, for the 12 months ending December 31, 2012, according to
IMS Health.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in